News & articles

Dear member of the MPN community, Each year when preparing this letter, the reality of our accomplishments and the progress in the entire MPN community leave us with a great sense of pride and renewed hope for the future.  Walking the Walk To date, the MPN Research Foundation has awarded over $8.2 million for medical… Read More »LETTER FROM OUR VICE PRESIDENT OF DEVELOPMENT

At the recent ASH meeting, pharmaceutical company Eli Lily announced findings from their Phase I trial for LY2784544, a JAK2 inhibitor. They are developing this compound for the treatment of patients with JAK2 positive polycythemia vera, essential thrombocythemia or myelofibrosis. For more information please click here to be redirected to Eli Lily’s press release.

By Dr. Claire HarrisonGuy’s and St. Thomas’ Hospital, London, UK  I was very pleased to be asked to write on this topic. Just as there are gender differences in other aspects of life; specific concerns arise for women who have MPNs. Some of my colleagues thought the idea was “sexist” or “biased” but most also… Read More »WOMEN AND MPNS

A typical non-profit structure includes a board of directors, who oversee the organization at a high level and ensure the mission is being pursued, and staff, who execute the vision of the board. In between these levels there is the possibility for another layer: committees. Committees for non-profits are often comprised of people who are… Read More »WHAT ARE MPN RESEARCH FOUNDATION COMMITTEES?

MPN Research Foundation and The Leukemia & Lymphoma Society Partner to Spur Innovation in Fibrosis Research  In January 2012 the Myeloproliferative Neoplasm (MPN) Research Foundation and The Leukemia & Lymphoma Society (LLS) will jointly issue a Request for Proposals (RFP) seeking innovative approaches to reversing fibrosis in patients with myelofibrosis (MF).  Applicants for this concept… Read More »NEW GRANT OPPORTUNITY FOR MYELOFIBROSIS

April 2011 The Belgian Journal of Hematology recently published their review of the state of JAK Inhibitors. Since its discovery in 2005 several companies have been working on creating a JAK Inhibitor for treatment of the myeloproliferative neoplasms. Click here to read the full article (PDF) Current trials for polycythemia vera, essential thrombocythemia and myelofibrosis… Read More »EUROPEAN JOURNAL OFFERS REVIEW OF CURRENT JAK INHIBITORS

March 2011 The patients who run the MPD Foundation are impatient to see results from the medical research they fund. That’s understandable: their rare blood diseases – essential thrombocythemia, polycythemia vera and myelofibrosis, collectively called myeloproliferative neoplasms – are progressive, incurable and generally not well managed by existing medicines. So, in its latest round of… Read More »PATIENTS PUSH RESEARCHERS TO SHARE DATA

February 2011 The MPN Research Foundation (formerly MPD Foundation) is pleased to announce the recipients of its Established Investigator and New Investigator grants for 2011. These awards follow an extensive proposal review process conducted by the MPN Research Foundation’s Scientific Advisory Board as well as additional MPN experts who gave generously of their time and… Read More »2011 MPN RESEARCH FOUNDATION

January 2011 Geron Corporation has enrolled their first person in a Phase 2 clinical trial to test their drug (GRN163L) in patients with essential thrombocythemia. These drugs are aiming to target the leukemic stem cell, which Geron believes will “impact the biology of the disease”. This Phase 2 trial is testing the safety and efficacy… Read More »GERON ENROLLS FIRST PATIENT IN DRUG STUDY FOR ESSENTIAL THROMBOCYTHEMIA

December 2010 Incyte Corp. is currently working on phase II clinical trials for their JAK Inhibitor INCB18424. These trials are testing safety and efficacy of this drug, meant to relieve constitutional symptoms in ET and PV patients. Results were reported at the American Society of Hematology’s annual meeting. Click here for more information